Small steps of improvement in small-cell lung cancer (SCLC) within two decades: a comprehensive analysis of 484 patients

Autor: Georg Pall, Gabriele Gamerith, G. Zangerl, Florian Kocher, William Sterlacci, Christian Waldthaler, Willi Oberaigner, Herbert Jamnig, Michael Fiegl, Andreas Pircher, August Zabernigg, M Nevinny, Wolfgang Hilbe, Thomas Schmid

Publikováno v: Lung cancer (Amsterdam, Netherlands). 84(2)

Background It is not clear whether or not the fate of patients suffering from small-cell lung cancer (SCLC) has improved. To better understand the course of disease, we aimed at documenting disease features at initial diagnosis, sequences of therapy

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::685e3638f4a9bb0c7938f2e088a7d8fb
https://pubmed.ncbi.nlm.nih.gov/24646832

SAT0074 No Need To Detect Anti-Drug Antibodies in Patients Treated with Tnf Inhibitors

Autor: T. Haueis, L. Boso, Manfred Herold, Werner Klotz, G. Zangerl

Publikováno v: Annals of the Rheumatic Diseases. 75:691.3-692

Background Formation of anti-drug antibodies (ADA) might be responsible for sub-therapeutic serum drug levels resulting in a lack of clinical response. The need to test ADA levels in patients treated with a TNF inhibitor is the subject of discussion

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::c0aef7b08741215a9ee51f204687f041
https://doi.org/10.1136/annrheumdis-2016-eular.5334

CT comparison of the nasal airway anterior and posterior to the piriform aperture in patients with and without nasal obstruction.

Autor: Heppt, Helen¹ (AUTHOR), Widmann, Gerlig² (AUTHOR), Riechelmann, Felix³ (AUTHOR), Runge, Annette¹ (AUTHOR), Riechelmann, Herbert¹ (AUTHOR), Giotakis, Aris I.¹ (AUTHOR) arisgiotakis@gmail.com

Publikováno v: Head & Face Medicine. 3/27/2024, Vol. 20 Issue 1, p1-11. 11p.

Phase II Study of Amrubicin in Patients with Refractory or Resistant Relapsed Small-Cell Lung Cancer: Japan Clinical Oncology Group Study (JCOG0901)

Autor: Masaharu Nishimura, G. Galffy, Q. Cheng, N. Stjepanovic, B. B. Oven Ustaalioglu, M.A. Damiano, G. Sajjady, J. Cai, B. Wallin, J. Dimitroulis, M. Reck, Judit Kocsis, B. Dome, S. Mellor, Y. Okuma, G. Le Teuff, N. Muzzafar, S. Yang, T. Tamura, S.A. Kazmi, G. Fust, H. Isobe, L. Graf, R. Eckert, D. Easty, S. Ahn, M. Chacon, D.A. Fennell, H. Daga, D. Pérez-Callejo, Raffaele Califano, Y. Ohe, Angela C. Casbard, Pablo Martinez, Y. Hosomi, H. Murakami, M. Salcedo, Y-C. Kim, Mustafa Canhoroz, Y. Fujita, A. Verlicchi, I. Oh, M.A. Burgio, S. Imtiaz, C. Kurkjian, M.A. Montero, A. Rosales, D. Pérez Callejo, C. Park, P. Ibeas, Susana Cedres, S. Heavey, Thierry Jahan, X. Wang, K. Kim, G. Stathopoulos, W. Sterlacci, M. Palka, N.B. Leighl, Satoshi Oizumi, Benjamin Besse, E. Almagro Casado, G. Gavelli, M. Yomoda, K. Takamura, C. Maximiano, J.W. Heyburn, Selcuk Seber, C. Lou, Wolfgang Hilbe, L. Tamasi, W. Mao, L. Ampollini, A. Santo, Jason F. Lester, D. Simos, H. Yang, J-C. Soria, H. Jamnig, S. Kuom, H. Ban, S. Sanna, Gareth Griffiths, Y. Ichinose, K. Na, D. Tsavdaridis, Taner Korkmaz, Z. Segota, R. Buosi, Lisette Sheena Nixon, G. Pall, K.A. Gately, M. Leschke, C. Martin, T. Schmid, P. Godwin, Hirotoshi Dosaka-Akita, M.E. Guiterrez, L. Lei, J. Edwards, C. Ho, Z. Prohaszka, David Planchard, H. Lu, Athanassios Argiris, J. Qin, M. Nevinny, Yvonne Summers, Y. Takagi, M. Endo, K.J. O'Byrne, T. Okamura, Z. Orosz, B. Cantos, A. Martinez, A. Falco, M. Mezzetti, E. Flechter, H. Watanabe, Umut Kefeli, G. Zangerl, M.S. Liew, R. Hassan, Serdar Turhal, A.C. Mita, I.A. Muazzam, Z. Bartfai, D. Nonaka, O.S. Breathnach, M. Monti, Harvey I. Pass, C. Poleri, O. Balvan, S. White, L. Mutti, J. Margery, W. Kim, Hedy L. Kindler, Hajime Asahina, M. Rosenberg, Mahmut Gumus, A. Pircher, A. López-González, N. Siddiqui, D. Torrejon Castro, V. Vilchez, R. Chacon, Dean A. Fennell, K. Umezawa, A. Szilagyi, T. Kojima, R. Mastico, Enriqueta Felip, Y. Zhang, P. Wheatley-Price, R. Guild, Rastilav Bahleda, D. Traphalis, M. Sergi, O. Ben Itzhak, T. Shibata, A.K. Patané, K. Das, S. Kumar, O. Vaisman, J. Stathopoulos, N. Yasar, W.M. Grogan, A. Soltermann, Steven G. Gray, H. Kang, J. Clince, M. Faehling, C.L. Hann, M. Barr, Lyudmila Bazhenova, B.G. Doger de Speville, A. Ruiz-Valdepeñas, Anne-Marie Baird, C. Kosmas, Y. Nakahara, T. Harada, J.D. Maltzman, M. Provencio Pulla, J. Parno, N. Yamamoto, M. Wollner, Antoine Hollebecque, David R. Spigel, Willi Oberaigner, Y. Kawai, M. Shibuya, E. Sari, E. Almagro-Casado, M. Mendez Garcia, N.J. Coleman, J. Raphael, Johanna C. Bendell, M. Fiegl, I. Opitz, G. Diaz, E. Jennions, Christophe Massard, G. Genestreti, M. Iguchi, P. Fatato

Publikováno v: Annals of Oncology. 23:ix492

Background Standard therapy for refractory or resistant relapsed small-cell lung cancer (SCLC) has not yet been established. We conducted an open-label, multicenter, non-randomized phase II study to confirm the efficacy and safety of amrubicin, a top

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::3285e282bfecba0a422afa8f2b2c30d7
https://doi.org/10.1093/annonc/mds415

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.